Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling

Drug Safety

Volumn 24, Issue 5, 2001, Pages 323-351

  Malik, M ^a   Camm, A J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; QUINIDINE; TERFENADINE;

CARDIOTOXICITY; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART PROTECTION; HEART RHYTHM; HUMAN; LONG QT SYNDROME; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RR INTERVAL; TACHYCARDIA; TORSADE DES POINTES;

EID: 0035021986     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124050-00001     Document Type: Review

References (175)

1. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population
2. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly
3. The prognostic values of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens
4. T axis as an indicator of risk of cardiac events in elderly people
5. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
6. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care
7. Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients
8. Torsades de pointes due to quinidine: Observations in 31 patients
9. Efficacy and safety of d,1-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest
10. Sex difference in risk of torsade de pointes with d,1-sotalol
11. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management
12. The effects of erythromycin on the electrocardiogram
13. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic
14. QT prolongation due to roxithromycin
15. Possible risk for cardiac arrhythmia related to intravenous erythromycin
16. A review of erythromycin-induced malignant tachyarrhythmia - Torsade de pointes. A case report
17. Clarithromycin associated with torsade de pointes
18. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs. Clinical and regulatory implications
19. Cardiovascular adverse effects of antipsychotic drugs
20. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide
21. Right bundle branch block, persistent ST segment elevation and sudden death: A distinct clinical and electrocardiographic syndrome. A multicenter report
22. Ionic mechanisms of regional action potential heterogeneity in the canine fight atrium
23. Characterization of the hyperpolarization-activated inward current in isolated human atrial myocytes
24. Ks, absent from undiseased human ventricular myocardium?
25. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: Tridimensional mapping of activation and recovery patterns
26. Electrophysiological substrate for Torsade de pointes: Dispersion of refractoriness or early afterdepolarizations
27. Role of interventricular dispersion of repolarization in acquired torsadede-pointes arrhythmias: Reversal by magnesium
28. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart
29. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study
30. + currents in cardiac cells: Comparison with terfenadine
31. Preclinical in vitro cardiac electrophysiology: A method of predicting arrhythmogenic potential of antihistamines in humans?
32. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists
33. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children
34. Second-generation antihistamines: The risk of ventricular arrhythmias
35. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist
36. Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes
37. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
38. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine
39. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG
40. + channels IKr and IKs
41. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes
42. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: Clinical experience in the intensive care unit
43. The use of Xenopus oocytes for the study of ion channels
44. Electrophysiological recordings from Xenopus oocytes
45. Gene transfer of membrane channel proteins
46. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872
47. Differential effects of antipsychotics and metabolites on action potentials recorded from rabbit Purkinje fibers: Relationship with clinical case reports of QT prolongation and torsade de pointes
48. + channel HERG
49. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration
50. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs
51. Electrophysiological effects of LU111995 on canine hearts: In vivo and in vitro studies
52. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
53. Electrocardiography in toxicological studies
54. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate
55. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrythmic effects in a canine model of torsade de pointes
56. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol
57. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block
58. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling
59. Experimental models of torsade de pointes
60. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome
61. + channel family by ebastine
62. Problems of heart rate correction in the assessment of drug induced QT interval prolongation
63. An analysis of time relations of electrocardiograms
64. Die Systolendauer im Elekrokardiogramm bei normalen Menschen und bei Herzkranken
65. Rate correction of the QT interval
66. A demonstration on man of electromotive changes accompanying the heart's beat
67. On time relation between systolic duration of heart and pulse rate
68. The normal duration of the electrocardiographic ventricular complex
69. The normal duration of the Q-T interval
70. The normal Q-T interval
71. An exponential formula for heart rate dependence of QT interval during exercise and pacing in humans: Reevaluation of Bazett's formula
72. Bazett's QT correction reviewed: Evidence that a linear QT correction for heart rate is better
73. Relation between QT interval and heart rate: Applications and limitations of Bazett's Formula
74. An improved method for adjusting the QT interval for heart rate (the Framingham study)
75. Estimation of QT prolongation: A persistent, avoidable error in computer electrocardiography
76. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values
77. Dependence of resting QTc interval on clinical characteristics of survivors of acute myocardial infarction: Comparison of rate correction formulae
78. Andarrhythmic drugs and torsade de pointes
79. If Dr Bazett had had a computer
80. 'Optimum' formulae for heart rate correction of the QT interval
81. No single formula for heart rate correction of the QT interval is suitable for all individuals
82. The 24-hour QT/RR relation in healthy subjects is reproducible in the short- and long term
83. Short- and long-term reproducibility of the QT/RR relationship in healthy subjects
84. Abnormalities of the QT interval in primary disorders of autonomic failure
85. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: Significance for the control of sudden cardiac death
86. Effect of verapamil on QT interval dynamicity
87. Effects of sotalol on the circadian of heart rate and QT intervals with a noninvasive index of reverse-use dependency
88. Computerised measurement of QT dispersion in healthy subjects
89. Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event
90. Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events
91. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome
92. Circadian variation of the QT interval in patients with sudden cardiac death after myocardial infarction
93. Bazett formula is not suitable for assessment of the circadian variation of the heart-rate corrected QT interval
94. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate
95. Etiology of QT prolongation and T wave changes in chronic alcoholism
96. Prolonged QT interval in alcoholic autonomic nervous dysfunction
97. Prolonged QT interval and cocaine use
98. Cocaine abuse: Repolarization abnormalities and ventricular arrhythmias
99. Purkinje repolarization as a possible cause of the U wave in the electrocardiogram
100. Physiologic basis of the U wave
101. The role of M cells in acquired long QT syndrome, U waves and torsade de pointes
102. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome
103. Interobserver reproducibility of QT interval measurement and QT dispersion in patients after acute myocardial infarction
104. Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue
105. The measurement of the Q-T interval of the electrocardiogram
106. Human precision of operating a digitizing board: Implications for electrocardiogram measurement
107. Comparison of different methods for manual P wave duration measurement in 12-lead electrocardiograms
108. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: Results of a prospective, long-term follow-up study
109. Computer system for measurement of QT and QU intervals and for evaluation of QT dispersion in standard 12 lead electrocardiograms
110. QT interval and QT dispersion measured with the threshold method depend on threshold level
111. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals
112. Long QT: Good, bad, indifferent and fascinating
113. Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects
114. Influence of lead selection and population on automated measurement of QT dispersion
115. Wilt QT dispersion play a role in clinical decisionmaking?
116. QT and dispersion of ventricular repolarization: The greatest fallacy in electrocardiography in the 1990s
117. Measurement, interpretation and clinical potential of QT dispersion
118. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences
119. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram
120. Changes in the pharmacokinetics and electrocardiographic pharmacokinetics of terfenadine with concomitant administration of erythromycin
121. Grapefruit juice alters the systemic bioavailability and cardiac repolarisation of terfenadine in poor metabolizers of terfenadine
122. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine
123. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine
124. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters
125. Effect on dirithromycin on human CYP3A in vivo and on pharmacokinetics and pharmacodynamics of terfenadine in vivo
126. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics
127. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men
128. Azithromycin and terfenadine: Lack of drug interaction
129. Effects of zafirlukast on QTc and area under the curve on terfenadine in healthy men
130. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice
131. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine
132. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
133. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride
134. Oral amiodarone
135. Female gender as a risk factor for drug-induced cardiac arrhythmias: Evaluation of clinical and experimental evidence
136. Greater quinidine-induced QTc interval prolongation in women
137. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada
138. Cisapride
139. FDA, Janssen holster cardiac risk warnings for cisapride
140. Q-T prolongation and polymorphous ('torsade de pointes') ventricular arrhythmias associated with organophosphorus insecticide poisoning
141. Death from fluoro-silicate in floor polish
142. Cardiovascular safety of fexofenadine HC1
143. QT lengthening and life-threatening arrhythmias associated with fexofenadine
144. Inhibition of HERG potassium channels by the antimalarial agent halofantrine
145. Prolonged QT interval with halofantrine
146. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome
147. Sudden deaths while on halofantrine treatments - A report of two cases from Peshawar
148. An integrated assessment of the clinical safety of artemether-lumefantrine: A new oral fixed-dose combination antimalarial drug
149. Mechanism of cardiotoxicity of halofantrine
150. Pharmacies and prevention of potentially fatal drug interactions
151. Use of terfenadine and contraindicated drugs
152. Janssen Propulsid prescribing for inpatients questioned in three studies
153. QT interval measurement by a computer assisted program: A potentially useful clinical parameter
154. An improved method for the precise measurement of serial ECG changes in QRS duration and QT interval. Performance assessment on the CSE noise-testing database and a healthy 720 case-set population
155. Automated measurement of QT interval dispersion from hard-copy ECGs
156. Automatic detection of wave boundaries in multilead ECG signals: Validation with the CSE database
157. Are serial Holter QT, late potential, and wavelet measurement clinically useful?
158. Analysis of interval measurements on CSE multilead reference ECGs
159. Performance of an electrocardiographic analysis system: Implications for pharmacodynamic studies
160. Reproducibility and automatic measurement of QT dispersion
161. Algorithms for computerized QT analysis
162. Using simulated noise to define optimal QT intervals for computer analysis of ambulatory ECG
163. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion
164. A new approach for TU complex characterization
165. Spatial, temporal and wavefront direction characteristics of 12-lead T wave morphology
166. Analysis of twelve-lead T wave morphology for risk stratification after myocardial infarction
167. T-wave morphology differentiates between patients with and without arrhythmic complications of ischaemic heart disease
168. Spectrum of ST-Twave patterns and repolarisation parameters in congenital long-QT syndrome: ECG findings identify genotypes
169. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
170. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias
171. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia
172. From genes to channels: Normal mechanisms
173. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem